We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals

30 hedge funds and large institutions have $80.6M invested in Xenon Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

151% more capital invested

Capital invested by funds: $32M → $80.6M (+$48.5M)

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

43% more funds holding

Funds holding: 2130 (+9)

Holders
30
Holders Change
+9
Holders Change %
+42.86%
% of All Funds
0.8%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
9
Increased
8
Reduced
5
Closed
Calls
Puts
Net Calls
Net Calls Change

XENE Hedge Fund Activity: Q3 2016 in Review

30 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2016, worth a combined $80.6M — up 151% from $32M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new XENE positions and 0 closed out — a net gain of 9 holders — while 8 added to existing stakes and 5 trimmed.

The largest buyer was BVF Inc, adding an estimated $10.3M. The largest seller was Royal Bank of Canada, cutting an estimated $194K.

  • 30 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2016, up from 21 in Q2 2016.
  • Funds reported $80.6M of Xenon Pharmaceuticals stock for Q3 2016, up 151% quarter-over-quarter.
  • 9 funds opened new Xenon Pharmaceuticals positions in Q3 2016 and 0 closed out, a net change of +9 holders.
  • The largest Xenon Pharmaceuticals buyer in Q3 2016 was BVF Inc, an estimated $10.3M added.
  • The largest Xenon Pharmaceuticals seller in Q3 2016 was Royal Bank of Canada, an estimated $194K sold.

Based on aggregated 13F filings for Q3 2016.